Innate Pharma的年度收入达到900万欧元，较去年同期的230万欧元有所增长；现金储备则达到了9680万欧元。该公司首席财务官弗雷德里克·隆巴德计划于12月31日离职。

2026-11-05 15:52

Phase 1 dose-escalation data for Nectin-4 ADC IPH4502 to be presented at ENA 2026 on November 18, followed by a webcast and in-person event
Lacutamab, partnered with Sobi, progressing toward first patient dosing in the Phase 3 TELLOMAK-3 trial in Q1 2027, with an FDA accelerated approval filing planned in Sézary syndrome in H2 2027
AstraZeneca-led PACIFIC-9 Phase 3 trial of durvalumab in combination with monalizumab or oleclumab in unresectable Stage III NSCLC, readout expected in the first half of 2027
Cash position of €96.8 million1 as of September 30, 2026; anticipated cash horizon until the end of Q1 2028